Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction
机构：[1]Binzhou Medical University, Yantai, Shandong, China[2]Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China[3]Department of Urology, Qixia People’s Hospital, Yantai, Shandong, China[4]Department of Urology, Beijing TianTan Hospital, Capital Medical University, Beijing, China首都医科大学附属天坛医院
This meta-analysis was performed to evaluate the efficacy and safety of tadalafil plus tamsulosin compared with tadalafil alone in treating men with benign prostatic hyperplasia (BPH) and erectile dysfunction (ED) after 12 weeks' treatment. Systematic review was carried out using the Preferred Reporting Items for Systematic Reviews and Meta-analyses. MEDLINE, EMBASE, and the Cochrane Controlled Trials Register were searched to collect randomized controlled trials. The references of related articles were also searched. Four articles including 621 patients were involved in the analysis. The study identified that combination-therapy had significant improvements in total international prostate symptom score (IPSS), quality of life (QoL) and maximum urine flow rate (Qmax) compared with monotherapy, and there were no obvious significance in respects of post-void residual volume, international index of erectile function and IPSS storage. The difference of total IPSS was mainly reflected in the change of IPSS voiding. For safety, combination-therapy had a higher incidence rate of any adverse events (AEs) and discontinuation due to AEs than monotherapy with the exception of pain. In conclusion, the combination of tadalafil and tamsulosin provided a better improvement of IPSS voiding, QoL and Qmax compared with tadalafil alone in treating men with BPH and ED, and the former therapy appeared to show a higher incidence of AEs.
基金：
This work was supported by the National Nature Science
Foundation of China (81572835, 81801429, 81870525), and by
the Shandong Key Research and Development Program
(2018GSF118118).
语种：
外文
被引次数：
WOS：
中科院(CAS)分区：
出版当年[2018]版：
无
最新[2025]版：
大类|4 区医学
小类|4 区公共卫生、环境卫生与职业卫生
第一作者：
第一作者机构：[1]Binzhou Medical University, Yantai, Shandong, China[2]Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China
共同第一作者：
通讯作者：
通讯机构：[2]Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, Yantai, Shandong, China[4]Department of Urology, Beijing TianTan Hospital, Capital Medical University, Beijing, China[*1]Department of Urology, The Affiliated Yantai Yuhuangding Hospital of Qingdao University, No. 20 East Yuhuangding Road, Yantai, Shandong 264000, China and Department of Urology, Beijing TianTan Hospital, Capital Medical University, No. 119 South 4th Ring West Road, Fengtai District, Beijing 100070, China.
推荐引用方式(GB/T 7714)：
Zhongbao Zhou,Xuesong Zheng,Jitao Wu,et al.Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction[J].AMERICAN JOURNAL OF MENS HEALTH.2019,13(5):-.doi:10.1177/1557988319882597.
APA：
Zhongbao Zhou,Xuesong Zheng,Jitao Wu,Zhenli Gao,Zhunan Xu&Yuanshan Cui.(2019).Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction.AMERICAN JOURNAL OF MENS HEALTH,13,(5)
MLA：
Zhongbao Zhou,et al."Meta-Analysis of Efficacy and Safety of Tadalafil Plus Tamsulosin Compared with Tadalafil Alone in Treating Men with Benign Prostatic Hyperplasia and Erectile Dysfunction".AMERICAN JOURNAL OF MENS HEALTH 13..5(2019):-
